Intranasal (IN) Ketamine in Treatment Resistant Depression (TRD)

ID Number 11-0492

Principal Investigator(s)
James Murrough

Department(s) or Division(s)


The objective of the current study is to investigate the safety and efficacy of a single dose of intranasal (IN) ketamine in treatment-resistant depression (TRD). We are looking for depressed participants suffering from Major Depressive Disorder (MDD) who have not improved after at least one medication treatment to participate in a research study with an investigational novel medication aiming to relieve symptoms of depression. Participants would have two separate outpatient stays at the Mount Sinai Hospital, each one week apart, then follow-up visits in our clinic. Eligible participants will receive treatment at no cost to them and compensation for their time.

Contact Information
Jaclyn Schwartz
(212) 241-3116

Recruiting Patients: Yes